TY - JOUR
T1 - Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma
T2 - Final report of NABTT 97-11
AU - Batchelor, Tracy T.
AU - Gilbert, Mark R.
AU - Supko, Jeffrey G.
AU - Carson, Kathryn A.
AU - Nabors, Louis B.
AU - Grossman, Stuart A.
AU - Lesser, Glenn J.
AU - Mikkelsen, Tom
AU - Phuphanich, Surasak
PY - 2004/1
Y1 - 2004/1
N2 - The primary objective of this study was to determine the proportion of patients exhibiting a radiographic response in a cohort of patients with recurrent malignant glioma who were treated with irinotecan. Secondary objectives were to determine progression-free survival, overall survival, and toxicity. The trial was terminated after the first 18 patients were enrolled in this multicenter, 2-stage, phase 2 study. Twelve patients received concurrent enzyme-inducing antiepileptic drugs, and 6 did not. Each cycle consisted of a 90-min i.v. infusion of irinotecan every week for 4 consecutive weeks, followed by 2 weeks off. One patient had a complete response, 5 patients had stable disease, 5 patients had radiographic progression, 6 patients were removed from the study because of toxicity, and 1 patient refused further therapy and was removed from the study. The response rate in this study was 6% (1/18), and 28% (5/18) of these patients progressed while receiving irinotecan. Dose-limiting toxicities consisted of diarrhea in 5 patients, neutropenia in 1 patient, infection in 1 patient, and respiratory failure in 1 patient. Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations.
AB - The primary objective of this study was to determine the proportion of patients exhibiting a radiographic response in a cohort of patients with recurrent malignant glioma who were treated with irinotecan. Secondary objectives were to determine progression-free survival, overall survival, and toxicity. The trial was terminated after the first 18 patients were enrolled in this multicenter, 2-stage, phase 2 study. Twelve patients received concurrent enzyme-inducing antiepileptic drugs, and 6 did not. Each cycle consisted of a 90-min i.v. infusion of irinotecan every week for 4 consecutive weeks, followed by 2 weeks off. One patient had a complete response, 5 patients had stable disease, 5 patients had radiographic progression, 6 patients were removed from the study because of toxicity, and 1 patient refused further therapy and was removed from the study. The response rate in this study was 6% (1/18), and 28% (5/18) of these patients progressed while receiving irinotecan. Dose-limiting toxicities consisted of diarrhea in 5 patients, neutropenia in 1 patient, infection in 1 patient, and respiratory failure in 1 patient. Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations.
UR - http://www.scopus.com/inward/record.url?scp=0942266258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0942266258&partnerID=8YFLogxK
U2 - 10.1215/S1152851703000218
DO - 10.1215/S1152851703000218
M3 - Article
C2 - 14769136
AN - SCOPUS:0942266258
SN - 1522-8517
VL - 6
SP - 21
EP - 27
JO - Neuro-oncology
JF - Neuro-oncology
IS - 1
ER -